Financials
- Financial year
- 2025
- Turnover
- €14.7m
- Loss
- -€374,469
- Solvency
- 2.0%
Turnover▲ 4.3%
Net result
20212025
Magis-Pharma
ActiveSummary
The computed 12-month bankruptcy probability of Magis-Pharma is 1.6% (moderate). The annual accounts of Magis-Pharma for financial year 2025 show a net loss of 60% of the equity at the start of that year. The 2025 annual accounts show equity of €247,993 and a net result of -€374,469. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 9% of 6,139 sector peers (NACE 46, financial year 2025). The company has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
Wholesale of pharmaceutical and medical goods
NACE 46460
Fastest staff growth in the province of Antwerp, Wholesale trade sector2 sites
Size
€14.7mturnover 2025
- Staff
- 55.2 FTE
- Equity
- €247,993
- Loss
- -€374,469
Net result +74%: merger
Structure
- Parent
- MAGIS PHARMA · 100%
- Board
- 4 members
- DB ConsortiumManaging director · permanent representative Daan Bergers
Auditor: NV Callens Vandelanotte2025 accounts 15 days early9 of 21 deeds summarised
Why 53raises riskLiquidity: current ratio 1.16, cash €93,370, halved1 of the last 3 lateEquity €247,993 (2.0% of total assets)Loss of €374,469, the second in a row (financial year 2025)Show the evidence
Checked score
Score 2025
53
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 18% of its sector peers (NACE 46, medium-sized)
Financial strength · tick = 2024
Weak
Solvency
27-3
equity 2.0% of total assets
Liquidity
17+2
short-term debt 64.4% · cash 0.7%
Profitability
34+30
return on assets -3.0%
Bankruptcy probability, 12 months
1.6%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 1.1%
12-2024: 1.1%● unchanged vs 11-2024
01-2025: 1.1%● unchanged vs 12-2024
02-2025: 1.0%▼ -0.1 percentage points vs 01-2025lowest value
03-2025: 1.0%● unchanged vs 02-2025lowest value
04-2025: 1.2%▲ +0.2 percentage points vs 03-2025
05-2025: 1.4%▲ +0.2 percentage points vs 04-2025
06-2025: 1.5%▲ +0.1 percentage points vs 05-2025
07-2025: 1.6%▲ +0.1 percentage points vs 06-2025
08-2025: 2.3%▲ +0.7 percentage points vs 07-2025
09-2025: 3.2%▲ +0.9 percentage points vs 08-2025
10-2025: 6.6%▲ +3.4 percentage points vs 09-2025highest value
11-2025: 2.3%▼ -4.3 percentage points vs 10-2025
12-2025: 2.3%● unchanged vs 11-2025
01-2026: 2.3%● unchanged vs 12-2025
02-2026: 2.2%▼ -0.1 percentage points vs 01-2026
03-2026: 2.2%● unchanged vs 02-2026
04-2026: 2.2%● unchanged vs 03-2026
05-2026: 2.2%● unchanged vs 04-2026
06-2026: 2.3%▲ +0.1 percentage points vs 05-2026
07-2026: 2.4%▲ +0.1 percentage points vs 06-2026
08-2026: 1.6%▼ -0.8 percentage points vs 07-2026
09-2026: 1.6%● unchanged vs 08-2026
10-2026: 1.6%● unchanged vs 09-2026
Credit of up to €13,000 on 30-day terms, only on tighter conditions
Net loss of at least half of total assets or of the equity at the start of the financial year.
Liquidity tight (current ratio 1.16, compared with 0.93 in 2024, below the usual 1.5; short-term debt: 64.4% and cash: 0.7% of total assets), and 98% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, medium-sized): better than 7% on solvency, 17% on liquidity, 18% on profitability and 31% on growth.
The bankruptcy probability was computed on 24-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Seven signals.
raises riskneutral
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025Net result per financial year
1819202122232425
2018 to 2025 · latest year -€374,469
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 9% of 6139 sector peers (2025).
NBB · sector comparisonPosition among 6139 sector peers
Solvency
better than 9%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 16-07-2026, 15 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
15 days early
2024
84 days late
2023
93 days early
2022
3 days late
2021
32 days early
2020
9 days late
2019
22 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 9 days before the deadline; the sector median (NACE 46) for financial year 2024 is 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 16 July (4 of the last 5 filed years within 77 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
25-10-2026 today31-12-2026 year end31-07-2027 deadline
- Resignation: Jeroen van der Hamsvoort (director)Appointment: Constantijn van Rietschoten (director)…
- Capital & shares · RestructuringMerger · Accounting effect ·…
- Annual accounts filedfinancial year 2025 · full…
Key points
- Risk: 3 loss-making years in a rowloss financial year 2025 -€374,469 View
- Caution: Among the weakest 8% on net resultsector median €112,347 · 6,074 companies -€374,469 View
- Caution: Equity fell in 2025from €622,462 to €247,993 ▼ 60.2% View
- Board changedlatest change 31-08-2026 · 4 in office 3 joined · 3 left View
- 2 restructurings since 2024latest: merger with PARCHIM 2 View
- Controlled by MAGIS PHARMA 100% View
By topic
Board & ownership
- Board
- 4 members
- Parent
- MAGIS PHARMA · 100%
- Auditor
- NV Callens Vandelanotte
- GREEN MONKEYDaily manager
- Paulus de VogelDirector
- Constantijn van RietschotenDirector
- DB ConsortiumManaging director
Network & group
- Connected companies
- 7
- Mergers and asset contributions
- 2
Timeline
- Events
- 24
- Since
- 2017
- Next accounts
- by 31-07-2027
- 23-06-2026Restructuring
- 05-06-2026Resignations: DB Consortium, TJ Management and Vialma…
- 26-11-2025Reappointment: Callens Vandelanotte NV (statutory auditor)
Company details
- Sites
- 2
- Legal form
- Public limited company
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Founded
- 22-12-2015
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 3
- Purpose
- “De aanvraag, het beheer en de uitvoering van vergunningen voor het importeren, verwerken…” (deed in Dutch)
Key facts about Magis-Pharma
- What is the company number of Magis-Pharma?
- 0644.784.239. In Belgium the VAT number is the company number with BE in front: BE 0644.784.239.
- Where is Magis-Pharma based?
- The registered office is at Neerlandweg 24, 2610 Antwerpen.Company details
- What does Magis-Pharma do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of Magis-Pharma?
- Public limited company (NV).
- When was Magis-Pharma founded?
- On 22-12-2015.
- Is Magis-Pharma still active?
- Yes, Magis-Pharma is an active enterprise in the KBO register.
- How many employees does Magis-Pharma have?
- On average 55.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of Magis-Pharma?
- €14.7m in financial year 2025, according to the filed annual accounts.
- Is Magis-Pharma profitable?
- In financial year 2025, Magis-Pharma made a loss of €374,469.
- Where can I find the annual accounts of Magis-Pharma?
- Magis-Pharma filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Magis-Pharma due?
- By 31-07-2027, for financial year 2026.Timeline
Companies related to Magis-Pharma
Parent and group
- MAGIS PHARMA100%
Shareholders
Comparable companies
- D.E.N. MEDICALSchoten
- EQUI 4SHasselt
- DevyserBrussel
- COSMEDICBoechout
- DOHMEYER SCIENTIFIC APPLICATIONSRoeselare
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.